Am J Psychiatry 158:2008-2014, December 2001
© 2001 American Psychiatric Association
Placebo-Controlled Trial of Sertraline in the Treatment of Children With Generalized Anxiety Disorder
Moira A. Rynn, M.D.,
Lynne Siqueland, Ph.D., and
Karl Rickels, M.D.
OBJECTIVE: The study compared the safety and efficacy of sertraline, a selective serotonin reuptake inhibitor, and placebo in the treatment of generalized anxiety disorder in children and adolescents. METHOD: The study subjects were 22 children and adolescents age 5–17 years who met the DSM-IV criteria for generalized anxiety disorder according to the Anxiety Disorders Interview Schedule for Children—Revised and who had a Hamilton Anxiety Rating Scale score  16. The patients underwent a 2–3-week prestudy evaluation period, followed by a 9-week double-blind treatment phase in which they were randomly assigned in blocks of four to receive either sertraline or pill placebo. The maximum dose of sertraline was 50 mg/day. Primary outcome measures were the Hamilton anxiety scale and the Clinical Global Impression scale. RESULTS: The Hamilton anxiety scale total score, psychic factor, and somatic factor and the Clinical Global Impression severity and improvement scales showed significant differences with treatment in favor of sertraline over placebo beginning at week 4. Self-report measures reflected these results at the end of treatment. CONCLUSIONS: The results of this double-blind, placebo-controlled trial suggest that sertraline at the daily dose of 50 mg is safe and efficacious for the treatment of generalized anxiety disorder in children and adolescents.
This article has been cited by other articles:
|
|
|
|
 
R. B. Hidalgo, L. A. Tupler, and J. R. T. Davidson
An effect-size analysis of pharmacologic treatments for generalized anxiety disorder
J Psychopharmacol,
November 1, 2007;
21(8):
864 - 872.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Bridge, S. Iyengar, C. B. Salary, R. P. Barbe, B. Birmaher, H. A. Pincus, L. Ren, and D. A. Brent
Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-analysis of Randomized Controlled Trials
JAMA,
April 18, 2007;
297(15):
1683 - 1696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Rynn, M. A. Riddle, P. P. Yeung, and N. R. Kunz
Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials
Am J Psychiatry,
February 1, 2007;
164(2):
290 - 300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Safer
Should Selective Serotonin Reuptake Inhibitors Be Prescribed for Children With Major Depressive and Anxiety Disorders?
Pediatrics,
September 1, 2006;
118(3):
1248 - 1251.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Allgulander, A. A. Dahl, C. Austin, P. L.P. Morris, J. A. Sogaard, R. Fayyad, S. P. Kutcher, and C. M. Clary
Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder
Am J Psychiatry,
September 1, 2004;
161(9):
1642 - 1649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Hoge, J. E. Oppenheimer, and N. M. Simon
Generalized Anxiety Disorder
Focus,
July 1, 2004;
2(3):
346 - 359.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Olfson, D. Shaffer, S. C. Marcus, and T. Greenberg
Relationship Between Antidepressant Medication Treatment and Suicide in Adolescents
Arch Gen Psychiatry,
October 1, 2003;
60(10):
978 - 982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Coghill
Current issues in child and adolescent psychopharmacology. Part 2: Anxiety and obsessive-compulsive disorders, autism, Tourette's and schizophrenia
Advan. Psychiatr. Treat.,
July 1, 2003;
9(4):
289 - 299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other Articles Noted
Evid. Based Ment. Health,
August 1, 2002;
5(3):
72 - 72.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
